what percent of americans are on glp 1 Big shift in U.S. health! A new Gallup poll shows 11% now taking GLP-1 drugs, coinciding with obesity rates dropping to 36.4% (down from 39.9% in 2022). Promising progress in Poll: 1 in 8 Adults

In this article we provide an overview of the pathophysiology and management of NASH, with a special focus on the pharmacological effects and possible mechanisms of GLP-1 mimetics in treating NAFLD/NASH, including dual and triple agonists at GLP-1R, glucose-dependent insulinotropic polypeptide receptor or glucagon receptor.

But for some, the drugs come with side effects they say aren't worth it.

I've noticed a common thread running through many of the GLP-1 forums and social media groups I follow

The FDA recently approved versions of GLP-1 medication - including Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide) - for chronic weight management

In fact, the similar pathological mechanisms shared by PD and T2DM have inspired several studies on the therapeutic potential of T2DM drugs against PD, among which glucagon-like peptide-1 receptor (GLP-1R) agonists are promising candidates

Several celebrities have sparked debate over their health journeys using GLP-1, a Type 2 diabetes drug.